Fair Value Measurement of Financial Instruments and Impairment Risk for Investment Securities
First written in FY2017-Q3. 20 of 25 entries say "Materialised", first in FY2019-Q3. Latest entry: FY2026.
Tokai Tokyo Financial Holdings moved to the "Worse" side of this theme in 2019, 1 year before the typical company in this theme (2020).
The whole theme swung hardest in 2019: 42 of 77 companies on the "Worse" side.
45 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「During the current consolidated fiscal year, impairment losses of ¥166 million were recognized on securities, comprising ¥166 million on shares classified as other securities.」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥166 million was actually recognized during the current consolidated fiscal year. - 2026-04-30MaterialisedOccurring Fact
「当社保有の CHEER 証券株式の評価を実質価額まで引き下げることとし、特別損失として 7,525 百万円を計上いたしました。」
CHEER証券株式について、実質価額までの評価引下げによる7,525百万円の特別損失が計上された。 - FY2026-H1MaterialisedAnnual report
「Non-operating expenses included an impairment loss on investment securities of ¥242 million and a loss on management of an investment partnership of ¥106 million, among other items. Total non-operating expenses increased 0.6% to ¥450 million. An extraordinary loss of ¥226 million was recognized.」
Regarding impairment losses on investment securities, ¥242 million was recognized in non-operating expenses and ¥160 million in extraordinary losses, and an impairment loss was also incurred during the current interim consolidated accounting period. - FY2025-H1MaterialisedAnnual report
「An impairment loss on investment securities of ¥323 million and other losses were recognized」
Regarding the valuation and impairment risk for financial instruments, an impairment loss on investment securities of ¥323 million was recognized during the current interim consolidated accounting period. - FY2024MaterialisedAnnual report
「During the current consolidated fiscal year, impairment losses of ¥278 million were recognized on securities, comprising ¥278 million on shares classified as other securities.」
Regarding the valuation and impairment risk for financial instruments, an impairment loss on securities of ¥278 million was actually recognized during the current consolidated fiscal year. - FY2024-Q3MaterialisedAnnual report
「Impairment loss on investment securities 268」
Regarding the valuation and impairment risk for financial instruments, an impairment loss on investment securities of ¥268 million was recognized during the nine months ended [the third quarter of] the current consolidated fiscal year. - FY2024-Q2MaterialisedAnnual report
「Impairment loss on investment securities 360」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥360 million was recognized during the six months ended [the second quarter of] the current consolidated fiscal year. - FY2024-Q1MaterialisedAnnual report
「Impairment loss on investment securities - 359」
Regarding the valuation and impairment risk for financial instruments, an impairment loss on investment securities of ¥359 million was recognized during the three months ended [the first quarter of] the current consolidated fiscal year. - FY2023-Q3MaterialisedAnnual report
「Impairment loss on investment securities 152」
Regarding the valuation and impairment risk for financial instruments, an impairment loss on investment securities of ¥152 million was recognized during the nine months ended [the third quarter of] the current consolidated fiscal year. - FY2023-Q2MaterialisedAnnual report
「An impairment loss on securities of ¥189 million and other losses were recognized as extraordinary losses.」
Regarding the valuation and impairment risk for financial instruments, an impairment loss on securities of ¥189 million was actually recognized during the six months ended [the second quarter of] the current fiscal year. - FY2022-Q3MaterialisedAnnual report
「Impairment loss on investment securities 252」
Regarding the valuation and impairment risk for financial instruments, an impairment loss on investment securities of ¥252 million was recognized during the nine months ended [the third quarter of] the current consolidated fiscal year. - FY2022-Q2MaterialisedAnnual report
「Impairment loss on investment securities 255」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥255 million was recognized during the six months ended [the second quarter of] the current consolidated fiscal year. - FY2022-Q1MaterialisedAnnual report
「Impairment loss on investment securities 229」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥229 million was recognized during the three months ended [the first quarter of] the current consolidated fiscal year. - FY2021-Q3MaterialisedAnnual report
「The main extraordinary gains for the nine months ended [the third quarter of] the current consolidated fiscal year were a gain on reversal of stock acquisition rights of ¥101 million and a reversal of the reserve for financial instruments transaction liabilities of ¥123 million, while the extraordinary loss was an impairment loss on investment securities of ¥264 million.」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥264 million was recognized during the nine months ended [the third quarter of] the current consolidated fiscal year. - FY2021-Q2MaterialisedAnnual report
「The main extraordinary gain for the six months ended [the second quarter of] the current consolidated fiscal year was a reversal of the reserve for financial instruments transaction liabilities of ¥123 million, while the extraordinary loss was an impairment loss on investment securities of ¥220 million.」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥220 million was actually recognized during the six months ended [the second quarter of] the current fiscal year. - FY2021-Q1MaterialisedAnnual report
「The main extraordinary loss for the three months ended [the first quarter of] the current consolidated fiscal year was an impairment loss on investment securities of ¥213 million.」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥213 million was actually recognized during the three months ended [the first quarter of] the current fiscal year. - FY2020MaterialisedAnnual report
「During the current consolidated fiscal year, impairment losses of ¥121 million were recognized on securities, comprising ¥121 million on shares classified as other securities.」
Regarding the valuation and impairment risk for financial instruments, an impairment loss of ¥121 million was recognized on securities during the current consolidated fiscal year. - FY2020-Q3MaterialisedAnnual report
「Impairment loss on investment securities 99」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥99 million was recognized during the nine months ended [the third quarter of] the current fiscal year. - FY2019MaterialisedAnnual report
「During the current consolidated fiscal year, impairment losses of ¥257 million were recognized on securities, comprising ¥257 million on shares classified as other securities.」
Regarding the impairment risk for investment securities, an impairment loss of ¥257 million was actually recognized during the current consolidated fiscal year. - FY2019-Q3MaterialisedAnnual report
「The main extraordinary loss was an impairment loss on investment securities of ¥224 million.」
Regarding the valuation and impairment risk for investment securities, an impairment loss of ¥224 million was actually recognized during the nine months ended [the third quarter of] the current fiscal year. - FY2019-Q2RestatedAnnual report
「Securities and derivatives and other instruments without quoted market prices are measured using estimated prices based on present values calculated primarily from interest rates, dividend yields, the prices of underlying securities, swap rates, volatility and contract terms. Their fair values may change if different assumptions or other factors are used.」
The disclosure continues to describe the risk of fair value changes arising from valuation assumptions for financial instruments without quoted market prices and the possibility of impairment resulting from deterioration in market conditions for investment securities and other factors. - FY2019-Q1RestatedAnnual report
「Securities and derivatives and other instruments without quoted market prices are measured using estimated prices based on present values calculated primarily from interest rates, dividend yields, the prices of underlying securities, swap rates, volatility and contract terms. Their fair values may change if different assumptions or other factors are used.」
The disclosure continues to describe the risk of fair value changes arising from valuation assumptions for financial instruments without quoted market prices and the possibility of impairment resulting from deterioration in market conditions for investment securities and other factors. - FY2018-Q3RestatedAnnual report
「Securities and derivatives and other instruments without quoted market prices are measured using estimated prices based on present values calculated primarily from interest rates, dividend yields, the prices of underlying securities, swap rates, volatility and contract terms. Their fair values may change if different assumptions or other factors are used.」
The disclosure continues to describe the risk of fair value changes arising from financial instrument valuation assumptions and the possibility of impairment resulting from deterioration in market conditions or poor performance by investees. - FY2018-Q2RestatedAnnual report
「Securities and derivatives and other instruments without quoted market prices are measured using estimated prices based on present values calculated primarily from interest rates, dividend yields, the prices of underlying securities, swap rates, volatility and contract terms. Their fair values may change if different assumptions or other factors are used.」
The disclosure continues to describe the possibility that valuation assumptions for financial instruments without quoted market prices may change fair values, and that deterioration in market conditions or investee performance may result in impairment. - FY2017-Q3First statedAnnual report
「Securities and derivatives and other instruments without quoted market prices are measured using estimated prices based on present values calculated primarily from interest rates, dividend yields, the prices of underlying securities, swap rates, volatility and contract terms. Their fair values may change if different assumptions or other factors are used. For listed shares, a decline is judged to be other than temporary when, among other circumstances, the market value of the shares remains at least 30% below acquisition cost for a certain period. For unlisted shares, impairment is recognized when net assets per share fall to 50% or less of acquisition cost. If future deterioration in market conditions or poor performance by investees results in losses not reflected in the current carrying amount, or makes the carrying amount unrecoverable, impairment may become necessary.」
The disclosure describes the risk that valuation assumptions for financial instruments without quoted market prices, and deterioration in market conditions or investee performance for investment securities, may lead to changes in fair value or impairment losses.